CD34 and acute myeloid leukemia: AML M3 was extensively studied by Payton et al. [63] who compared the malignant promyelocytes from APL patients to leukemic cells collected from other AML subtypes and to promyelocytes, neutrophils and CD34+ cells extracted from healthy bone marrow donors.